
NeuroSense Therapeutics Ltd (NASDAQ:NRSN) shares are soaring Monday after the company announced it received U.S. Food and Drug Administration clearance to initiate a pharmacokinetic study of PrimeC in healthy adult subjects.
PrimeC is designed to synergistically target several key mechanisms of amyotrophic lateral sclerosis (ALS). It's composed of a unique fixed-dose combination of two FDA-approved drugs: ciprofloxacin and celecoxib.